OcuMension
歐 康 維 視

Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY AND CHANGE IN AUTHORIZED REPRESENTATIVE

The board of directors (the "**Board**") of Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") announces that due to personal reasons, Mr. Tim RUAN (阮添士) ("**Mr. Ruan**") has tendered his resignation as the chief financial officer of the Company (the "**CFO**"), a joint company secretary of the Company (the "**Joint Company Secretary**") and an authorized representative of the Company (the "**Authorized Representative**"), under the Rules (the "**Listing Rules**") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), with effect from June 30, 2026.

Mr. Ruan has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange.

Following Mr. Ruan's resignation as the CFO, the Group's financial matters will continue to be managed by the finance team led by the finance director of the Company. The Board is of the view that Mr. Ruan's resignation will not have any material adverse impact on the financial operations and management of the Group.

Following the resignation of Mr. Ruan, Ms. Tingchan CHEN (陳聽蟬) ("**Ms. Chen**"), currently the other Joint Company Secretary, will act as the sole company secretary of the Company and an Authorized Representative with effect from June 30, 2026. Ms. Chen possesses the requisite qualifications of a company secretary as stipulated under Rules 3.28 and 8.17 of the Listing Rules. She has years of experience in corporate governance and company secretarial practices and has been an associate member of The Hong Kong Chartered Governance Institute since July 2023. Since her appointment as a Joint Company Secretary in September 2023, Ms. Chen has actively participated in relevant professional training. The Board is satisfied that Ms. Chen is fully qualified to act as the sole company secretary of the Company. Therefore, the Company continues to comply with Rules 3.05, 3.28, and 8.17 of the Listing Rules.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Ruan for his valuable contributions to the Company during his terms of office and extend its warm welcome to Ms. Chen on her new appointment.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 30, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.